Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | KMO | O15229 | 5/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24929582 | 0.84 | KMO (0.33) | PDE4APDE4BPDE4CPDE4DKMO | |
| SCHEMBL24928649 | 0.84 | ACLY (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30153363 | 0.84 | ACLY (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22647963 | 0.82 | CREBBP (0.34) | KDM4C | |
| SCHEMBL23384085 | 0.82 | HDAC2 (0.32) | — | |
| SCHEMBL24928945 | 0.79 | — | — | |
| SCHEMBL30153223 | 0.77 | ACLY (0.38) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL30845556 | 0.77 | ACLY (0.38) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL24928646 | 0.70 | ACLY (0.45) | FFAR4 | |
| SCHEMBL22648202 | 0.70 | RORC (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |